Identification of 2-arylbenzimidazoles as potent human histamine H4 receptor ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 23, 2006, Pages 6043-6048

  Lee Dutra, Alice ^a   Arienti, Kristen L ^a   Buzard, Daniel J ^a   Hack, Michael D ^a   Khatuya, Haripada ^a   Desai, Pragnya J ^a   Nguyen, Steven ^a   Thurmond, Robin L ^a   Karlsson, Lars ^a   Edwards, James P ^a   Breitenbucher, J Guy ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Arylbenzimidazole; Histamine H4

Indexed keywords

BENZIMIDAZOLE DERIVATIVE;

ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; EVALUATION; LIGAND BINDING; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

ALDEHYDES; AMINES; BENZIMIDAZOLES; CATALYSIS; COMPUTER SIMULATION; HISTAMINE; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750508934     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.08.117     Document Type: Article

References (19)

1. Ash A.S.F., and Schild H.O. Br. J. Pharmacol. 27 (1966) 427
2. Black J.W., Duncan W.A.M., Durant C.J., Ganellin C.R., and Parsons E.M. Nature (London) 236 (1972) 385
3. Arrang J.M., Garbarg M., and Schwartz J.C. Nature (London) 302 (1983) 832
4. de Esch I.J.P., Thurmond R.L., Jongejan A., and Leurs R. Trends Pharmacol. Sci. 26 (2005) 462
5. Fung-Leung W.-P., Thurmond R.L., Ling P., and Karlsson L. Curr. Opin. Investig. Drugs 5 (2004) 1174
6. O'Reilly M., Alpert R., Jenkinson S., Gladue R.P., Foo S., Trim S., Peter B., Trevethick M., and Fidock M. J. Recept. Signal Transduct. Res. 22 (2002) 431
7. Hofstra C., Desai P.J., Thurmond R.L., and Fung-Leung W.-P. J. Pharmacol. Exp. Ther. 305 (2003) 1212
8. Buckland K.F., Williams T.J., and Conroy D.M. Br. J. Pharmacol. 140 (2003) 1117
9. Thurmond R.L., Desai P.J., Dunford P.J., Fung-Leung W.-P., Hofstra C.L., Jiang W., Nguyen S., Riley J.P., Sun S., Williams K.N., Edwards J.P., and Karlsson L. J. Pharmacol. Exp. Ther. 309 (2004) 404
10. Ling P., Ngo K., Nguyen S., Thurmond R.L., Edwards J.P., Karlsson L., and Fung-Leung W.-P. Br. J. Pharmacol. 142 (2004) 1
11. Venable J.D., Cai H., Chai W., Dvorak C.A., Grice C.A., Jablonowski J.A., Shah C.R., Kwok A.K., Ly K.S., Pio B., Wei J., Desai P.J., Jiang W., Nguyen S., Ling P.L., Wilson S.J., Dunford P.J., Thurmond R.L., Lovenberg T.W., Karlsson L., Carruthers N.I., and Edwards J.P. J. Med. Chem. 48 (2005) 8289
12. Jablonowski J.A., Grice C.A., Chai W., Dvorak C.A., Venable J.D., Kwok A.K., Ly K.S., Wei J., Baker S.M., Desai P.J., Jiang W., Wilson S.J., Thurmond R.L., Karlsson L., Edwards J.P., Lovenberg T.W., and Carruthers N.I. J. Med. Chem. 46 (2003) 3957
13. Arienti K.L., Brunmark A., Axe F.U., McClure K., Lee A., Blevitt J., Neff D.K., Huang L., Crawford S., Pandit C.R., Karlsson L., and Breitenbucher J.G. J. Med. Chem. 48 (2005) 1873
14. i values.
15. 4 receptor.
16. Accelrys Inc., Catalyst, Release 4.7, San Diego: Accelrys Inc., 2002.
17. Molecular Operating Environment (MOE), version 2001.01; Chemical Computing Group Inc.: Montreal, Canada, 2001.
18. Marshall G.R., Barry C.D., Bosshard H.E., Dammkoehler R.A., and Dunn D.A. In: Olsen E.C., and Christoffersen R.E. (Eds). Computer-Assisted Drug Design Vol. 112 (1979), American Chemical Society, Washington D.C. 205-226
19. 4 receptor binding.